Survival benefit of the homologous kidney allograft in simultaneous pancreas‐kidney transplants and its potential protective role

Serrano, Oscar K.; Kandaswamy, Raja; Finger, Erik B.

doi:10.1111/ctr.14462

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a study by O.K. Serrano et al in literature that reported on a possible role of homologous kidney graft on pancreas allograft 21 . Similar to our results, they showed that SPLK performance in terms of the pancreas graft survival was inferior to that of SPK owing to the possible protective role of homologous kidney graft on pancreas allograft when they were from the same donors as in SPK.…”

Section: Discussionmentioning

confidence: 99%

Comparison of long-term outcomes in simultaneous pancreas-kidney transplant versus simultaneous deceased donor pancreas and living donor kidney transplant

Kim

Choi

Kwon

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Simultaneous deceased donor pancreas and living donor kidney transplant (SPLK) has certain advantages over conventional simultaneous pancreas-kidney transplant (SPK) and may be beneficial for overcoming the paucity of organs needed for diabetic patients requiring transplant. We compared the clinical outcomes of patients who underwent either SPK (n = 149) or SPLK (n = 46) in terms of pre- and post-transplantation variables, development of de novo DSA, occurrence of biopsy-proven acute rejection (BPAR), and graft survival rates. There were no significant differences in the baseline characteristics between the SPK and SPLK groups except for the shorter cold ischemic time of kidney grafts, shorter duration of diabetes, older age of pancreas graft-donors, and younger age of kidney graft-donors in the SPLK group. Our results showed that the death-censored pancreas graft survival rate was lower in the SPLK group. In addition, the incidence of BPAR of the pancreas graft was higher in the SPLK group. There was no significant difference in the presence of de novo DSA and the rates of kidney graft failure, kidney BPAR, and mortality. Our results show that SPLK can be considered an alternative option for SPK although higher incidences of BPAR and graft failure of pancreas after SPLK need to be overcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of long-term outcomes in simultaneous pancreas-kidney transplant versus simultaneous deceased donor pancreas and living donor kidney transplant

Kim

Choi

Kwon

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

Simultaneous combined transplantation: Intricacies in immunosuppression management

Del Bello,

Vionnet,

Congy-Jolivet

et al. 2024

Transplantation Reviews

View full text Add to dashboard Cite

Evolution of Pancreas Transplantation At A Single Institution—50+ Years and 2500 Transplants

Finger,

Matar,

Dunn

et al. 2024

Annals of Surgery

View full text Add to dashboard Cite

Objective: To describe the evolution of pancreas transplantation, including improved outcomes and factors associated with improved outcomes over the past five decades. Background: The world’s first successful pancreas transplant was performed in December 1966 at the University of Minnesota. As new modalities for diabetes treatment mature, we must carefully assess the current state of pancreas transplantation to determine its ongoing role in patient care. Methods: A single-center retrospective review of 2,500 pancreas transplants performed over >50 years in bivariate and multivariable models. Transplants were divided into six eras; outcomes are presented for the entire cohort and by era. Results: All measures of patient and graft survival improved progressively through the six transplant eras. The overall death censored (DC) pancreas graft half-lives were >35 years for simultaneous pancreas and kidney (SPK), 7.1 years for pancreas after kidney (PAK), and 3.3 years for pancreas transplants alone (PTA). The 10-year DC pancreas graft survival rate in the most recent era was 86.9% for SPK recipients, 58.2% for PAK recipients, and 47.6% for PTA. Overall graft loss was most influenced by patient survival in SPK transplants, whereas graft loss in PAK and PTA recipients was more often due to graft failures. Predictors of improved pancreas graft survival were primary transplants, bladder drainage of exocrine secretions, younger donor age, and shorter preservation time. Conclusions: Pancreas outcomes have significantly improved over time via sequential, but overlapping, advances in surgical technique, immunosuppressive protocols, reduced preservation time, and the more recent reduction of immune-mediated graft loss.

show abstract

Survival benefit of the homologous kidney allograft in simultaneous pancreas‐kidney transplants and its potential protective role

Cited by 3 publications

References 24 publications

Comparison of long-term outcomes in simultaneous pancreas-kidney transplant versus simultaneous deceased donor pancreas and living donor kidney transplant

Comparison of long-term outcomes in simultaneous pancreas-kidney transplant versus simultaneous deceased donor pancreas and living donor kidney transplant

Simultaneous combined transplantation: Intricacies in immunosuppression management

Evolution of Pancreas Transplantation At A Single Institution—50+ Years and 2500 Transplants

Contact Info

Product

Resources

About